NATCO announces tentative approval to its ANDA for Trabectedin

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announced today that the U.S. Food and Drug Administration has granted tentative approval to its Abbreviated New Drug Application (ANDA) for Trabectedin for Injection (generic for Yondelis® ) for the 1mg/vial presentation.

According to industry sales data, Yondelis® generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market.

*All brand names and trademarks are the property of their respective owners.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 651.30 as compared to the previous close of Rs. 655.05. The total number of shares traded during the day was 34478 in over 2183 trades.

The stock hit an intraday high of Rs. 658.70 and intraday low of 649.50. The net turnover during the day was Rs. 22507292.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 USFDA TentativeApproval ANDA Trabectedin Injection